Clinical bottom line
Chronic cutaneous sarcoidosis remains a challenging granulomatous disorder with limited approved systemic therapies. Emerging evidence suggests that apremilast, a phosphodiesterase-4 inhibitor, and fumarate therapy may offer clinical benefit in selected patients with refractory or extensive skin involvement. However, data are limited primarily to small retrospective studies and early-phase trials, underscoring the need for further validation. Clinicians should consider these options cautiously, balancing potential efficacy against safety profiles and individual patient factors.
What the evidence shows
Cutaneous sarcoidosis manifests with diverse skin lesions that can be disfiguring and resistant to conventional treatments, including corticosteroids and immunosuppressants (Marcoval et al., 2011; SpringerReference, 2004). Systemic therapies targeting inflammatory pathways are often required for chronic or severe cases.
Apremilast has been investigated as a novel systemic agent for chronic cutaneous sarcoidosis. Baughman et al. (2012) reported on an open-label trial demonstrating that apremilast improved skin lesion severity and patient-reported symptoms with an acceptable safety profile. Earlier conference abstracts by the same group (Baughman et al., 2010) also suggested clinical benefit, although sample sizes were small and follow-up limited. The mechanism involves modulation of cyclic AMP and downstream inflammatory mediators implicated in granuloma formation.
Fumarate therapy, traditionally used in psoriasis, has been explored off-label for granulomatous skin diseases including sarcoidosis. Klein et al. (2012) conducted a retrospective study indicating that fumarates may reduce lesion size and inflammation in some patients refractory to standard therapies. However, this evidence is preliminary and derived from heterogeneous cohorts with variable dosing regimens.
Other systemic agents commonly used in sarcoidosis, such as corticosteroids and methotrexate, remain mainstays but carry risks of toxicity and relapse. The reviewed sources do not provide comparative efficacy data for these agents specifically in cutaneous sarcoidosis, highlighting a gap in robust head-to-head trials (Fadaie et al., 2025).
Caveats and uncertainty
The current evidence base for new systemic treatments in chronic cutaneous sarcoidosis is limited by small sample sizes, retrospective designs, and lack of randomized controlled trials. Apremilast studies have not yet established long-term efficacy or safety in larger, diverse populations. Similarly, fumarate therapy data are observational and may be confounded by concomitant treatments.
Heterogeneity in lesion morphology, disease chronicity, and systemic involvement complicates assessment of treatment response. Additionally, sarcoidosis pathogenesis is multifactorial and incompletely understood, which may affect therapeutic targeting (SpringerReference, 2004; Yamamoto et al., 2022).
Potential adverse effects of systemic therapies, including gastrointestinal symptoms with apremilast and lymphopenia with fumarates, require careful monitoring. The risk-benefit ratio must be individualized, especially in patients with comorbidities or concomitant immunosuppression.
How this may change practice
While corticosteroids and immunosuppressants remain first-line for chronic cutaneous sarcoidosis, emerging systemic agents like apremilast and fumarates represent promising alternatives for refractory cases. Dermatologists should consider these therapies within a multidisciplinary framework, ideally in consultation with sarcoidosis specialists.
Apremilast’s oral administration and favorable tolerability profile may enhance patient adherence compared to traditional immunosuppressants. Fumarate therapy could be an option for patients intolerant to or failing other systemic agents, though off-label use requires informed consent and close follow-up.
Future incorporation of these agents into treatment algorithms awaits confirmatory trials. Meanwhile, clinicians should remain vigilant for adverse effects and monitor disease activity objectively. Patient selection and shared decision-making are paramount given the current evidence limitations.